Overall, these results suggest that IFN-treatment may be effective in curbing SARS-CoV-2 infection, which was also observed in a phase-2 trial with nebulized IFN-β-1a showing better recovery in COVID-19 patients35. The gene discussed is IFNA1; the disease is COVID-19.